Novel strategies in the design and development of antivirals against dengue virus

设计和开发针对登革热病毒的抗病毒药物的新策略

• 批准号: LP0775507
• 负责人: Prof Suresh Mahalingam
• 金额: $ 11.37万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-05-05 至 2011-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0775507
• 关键词: Novel; strategies; design; development; antivirals

Globally, there are 50-100 million cases of dengue fever, with 500,000 cases of the more severe dengue haemorrhagic fever, each year. Australia has between 100 and 900 cases of dengue infection annually, often from travellers, but disease outbreaks occur in northern Australia. Effective anti-viral treatment will reduce disease burden. The project contributes to an evidence-based drug design program in collaboration with Australia's leading biotechnology industries. As a biotechnology industry project developing treatments for an emerging disease, it contributes to the national research priorities of Frontier technologies for building and transforming Australian industries, Promoting and maintaining good health and Safeguarding Australia.

在全球范围内，每年有5 000万至1亿例登革热病例，其中50万例为更严重的登革出血热病例。澳大利亚每年有100至900例登革热感染病例，通常来自旅行者，但疾病暴发发生在澳大利亚北方。有效的抗病毒治疗将减少疾病负担。该项目与澳大利亚领先的生物技术行业合作，为循证药物设计项目做出贡献。作为一个开发新兴疾病治疗方法的生物技术产业项目，它有助于国家前沿技术的研究重点，以建立和改造澳大利亚的产业，促进和保持良好的健康和保护澳大利亚。